Imaging Biomarkers for Glioma Treatment Response
神经胶质瘤治疗反应的成像生物标志物
基本信息
- 批准号:10025488
- 负责人:
- 金额:$ 27.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:Acetyl Coenzyme AAftercareAnalysis of VarianceAntineoplastic AgentsAreaAutomobile DrivingBehaviorBicarbonatesBiological MarkersBiomassBolus InfusionBrainCarbon DioxideCell ProliferationClinicClinicalClinical ResearchClinical TrialsCoenzyme Q10DataDeoxyglucoseDevelopmentEnergy MetabolismEquilibriumFollow-Up StudiesGliomaGlucoseGlycolysisGoalsImageIn VitroInjectableInjectionsLabelLeadLesionLongterm Follow-upMagnetic ResonanceMagnetic Resonance ImagingMalignant GliomaMalignant NeoplasmsMeasurementMeasuresMediatingMetabolicMetabolic PathwayMetabolismMitochondriaMorbidity - disease rateMultivariate AnalysisNodalNormal tissue morphologyOutcome MeasureOxidative PhosphorylationPatient-Focused OutcomesPatientsPatternPharmaceutical PreparationsPhase II Clinical TrialsPhenotypePilot ProjectsPositron-Emission TomographyPredictive ValueProcessProductionProgression-Free SurvivalsPyruvateRadiation therapyResearchResistanceSurrogate MarkersSuspensionsTestingTherapeuticTimeTimeLineTissuesTumor MarkersTumor VolumeWarburg Effectanti-cancercancer cellcarbon skeletonchemotherapeutic agentclinical translationconventional therapydriving forceearly phase clinical trialfirst-in-humanfluorodeoxyglucosefluorodeoxyglucose positron emission tomographyglucose metabolismglucose uptakeimage guidedimage guided interventionimaging biomarkerin vivoin vivo Modelinsightmetabolic imagingmultimodalitynanonovelnovel therapeutic interventionnovel therapeuticsoutcome predictionpredicting responsepreservationprimary outcomeresponsestandard measuresynergismtemozolomidetreatment responsetumortumor metabolismuptake
项目摘要
ABSTRACT
Alteration of metabolism so as to favor a preponderance of glycolysis (GLY) relative to oxidative
phosphorylation (OXPHOS) is considered a hallmark of cancer. Known originally as the Warburg effect, and
now considered part of the larger concept of metabolic reprogramming, these cellular changes represent a way
for cancer tissue to support rapid proliferation by preserving carbon skeletons for biomass production.
Understanding the mechanisms that underlie this metabolic shift is an active area of research. In the context
of therapeutics, insights from recent studies provide strong support that this reprogramming phenotype is
necessary and sufficient to support the cancer process, thus providing a basis for highly novel therapeutic
strategies in which either blocking or reversing metabolic reprogramming is the goal. Furthermore, malignant
gliomas, highly glycolytic cancers exceedingly resistant to conventional treatments, seem particularly suited to
approaches that can subvert this phenotype, and we believe the most crucial obstacle to moving such
therapies to clinic has been the inability to reliably measure in vivo response to such metabolic therapies.
The scientific premise of this proposal is that hyperpolarized 13C (HP13C) magnetic resonance imaging
(MRI) offers great promise in fulfilling this clinical need. Pyruvate (Pyr), located at a crucial juncture in the brain
glucose metabolic pathway where it can be either reduced to lactate (Lac) or converted to acetyl CoA + CO2,
which is then converted to bicarbonate (Bic), has the potential to be used as a HP13C surrogate marker of the
balance between GLY and OXPHOS. Following the bolus injection of HP [1-13C]Pyr, we propose that the
observed 13C-Lac/13C-Bic (Lac/Bic) ratios can be used as a quantitative biomarker of a changing balance
between these two metabolic processes, thus providing key information on glucose’s metabolic fate
complementary to the uptake information provided by more commonly available 18F-fluoro-deoxy-glucose
positron emission tomography (FDG-PET). Here, we propose to add simultaneous FDG-PET/HP13C/MRI
measurements to an upcoming Phase II clinical trial of malignant glioma treated with BPM31510 (Berg LLC), a
nano-suspension of Coenzyme Q10 showing high accumulation in cancer cell mitochondria and having marked
antitumor activity in multiple in vivo models (both alone and in combination with chemotherapeutic agents) with
in vitro evidence strongly suggesting the effect is mediated via increasing OXPHOS (i.e., reversing the
Warburg effect).
Our overall goal is to assess the potential synergy of combining information on glucose uptake, as provided
by FDG-PET, and glucose metabolism, as provided by HP13C, for tumor characterization, assessment of
therapeutic response, and prediction of patient outcome. If successful, the results from this pilot study would
provide the critical preliminary data to justify larger follow-up studies of the use of these imaging biomarkers
with anticancer metabolic therapies.
摘要
代谢的改变,从而有利于糖酵解(GLY)相对于氧化糖酵解(GLY)的优势
磷酸化(OXPHOS)被认为是癌症的标志。最初被称为瓦尔堡效应,
现在被认为是代谢重编程更大概念的一部分,这些细胞变化代表了一种方式,
通过保留碳骨架来生产生物质,使癌组织支持快速增殖。
了解这种代谢转变的机制是一个活跃的研究领域。背景下
最近研究的见解提供了强有力的支持,即这种重编程表型是
必要和足够的支持癌症过程,从而为高度新颖的治疗方法提供基础。
以阻断或逆转代谢重编程为目标的策略。此外,恶性
神经胶质瘤是一种高度糖酵解的癌症,对常规治疗极有抵抗力,似乎特别适合于
可以颠覆这种表型的方法,我们相信,
将代谢疗法应用于临床的困难在于不能可靠地测量对这种代谢疗法的体内反应。
这项建议的科学前提是,超极化13 C(HP 13 C)磁共振成像
(MRI)为满足这一临床需求提供了巨大的希望。丙酮酸(Pyr),位于大脑的关键部位
葡萄糖代谢途径,其中它可以被还原为乳酸(Lac)或转化为乙酰辅酶A + CO2,
然后转化为碳酸氢盐(Bic),具有用作HP 13 C替代标记物的潜力。
GLY和OXPHOS之间的平衡。推注HP [1- 13 C]Pyr后,我们提出,
观察到的13 C-Lac/13 C-Bic(Lac/Bic)比值可用作平衡变化的定量生物标志物
这两个代谢过程之间的联系,从而提供了关于葡萄糖代谢命运的关键信息
与更常见的18 F-氟脱氧葡萄糖提供的摄取信息互补
正电子发射断层扫描(FDG-PET)。在此,我们建议增加同步FDG-PET/HP 13 C/MRI
即将进行的用BPM 31510(贝格有限责任公司)治疗恶性胶质瘤的II期临床试验的测量,
辅酶Q10的纳米悬浮液显示在癌细胞线粒体中的高积累,
在多种体内模型(单独和与化疗剂组合)中的抗肿瘤活性,
体外证据强烈表明该作用是通过增加OXPHOS(即,扭转
瓦尔堡效应)。
我们的总体目标是评估结合葡萄糖摄取信息的潜在协同作用,
FDG-PET和葡萄糖代谢,如HP 13 C所提供,用于肿瘤表征,
治疗反应和患者结果的预测。如果成功,这项试点研究的结果将
提供关键的初步数据,以证明使用这些成像生物标志物的大型随访研究的合理性
抗癌代谢疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lawrence D Recht其他文献
Lawrence D Recht的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lawrence D Recht', 18)}}的其他基金
Imaging Biomarkers for Glioma Treatment Response
神经胶质瘤治疗反应的成像生物标志物
- 批准号:
10453751 - 财政年份:2020
- 资助金额:
$ 27.59万 - 项目类别:
Metabolic Therapy of GBM guided by MRS of hyperpolarized 13C-pyruvate
超极化13C-丙酮酸MRS引导的GBM代谢治疗
- 批准号:
9262926 - 财政年份:2014
- 资助金额:
$ 27.59万 - 项目类别:
Quantifying Cortical Neuron Production After Transplantation
移植后量化皮质神经元的产生
- 批准号:
7388436 - 财政年份:2007
- 资助金额:
$ 27.59万 - 项目类别:
CLINICAL TRIAL: DEXAMETHASONE-SPARING STUDY COMPARING (HERF) TO PLACEBO
临床试验:地塞米松节约研究 (HERF) 与安慰剂的比较
- 批准号:
7717882 - 财政年份:2007
- 资助金额:
$ 27.59万 - 项目类别:
CLINICAL TRIAL: HCRF FOR PATIENTS WITH MALIGNANT BRAIN TUMOR WHO REQUIRE HIGH-DO
临床试验:HCRF 适用于需要高剂量治疗的恶性脑肿瘤患者
- 批准号:
7717889 - 财政年份:2007
- 资助金额:
$ 27.59万 - 项目类别:
HCRF FOR PATIENTS WITH MALIGNANT BRAIN TUMOR WHO REQUIRE HIGH-DOSE DEXAMETHASONE
HCRF 适用于需要大剂量地塞米松的恶性脑肿瘤患者
- 批准号:
7605237 - 财政年份:2007
- 资助金额:
$ 27.59万 - 项目类别:
CLINICAL TRIAL: PERITUMORAL BRAIN EDEMA IN PATIENTS WITH PRIMARY MALIGNANT GLIOM
临床试验:原发性恶性胶质瘤患者的瘤周脑水肿
- 批准号:
7717893 - 财政年份:2007
- 资助金额:
$ 27.59万 - 项目类别:
CDOn: A Novel Marker of Neuronal Stem Cells
CDOn:神经元干细胞的新型标记物
- 批准号:
7647581 - 财政年份:2007
- 资助金额:
$ 27.59万 - 项目类别:
PERITUMORAL BRAIN EDEMA IN PATIENTS WITH PRIMARY MALIGNANT GLIOMA; (HCRF) TO DEX
原发性恶性胶质瘤患者的瘤周脑水肿;
- 批准号:
7605243 - 财政年份:2007
- 资助金额:
$ 27.59万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 27.59万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 27.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 27.59万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 27.59万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 27.59万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 27.59万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 27.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 27.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 27.59万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 27.59万 - 项目类别: